Oncology Companion Diagnostics Market by Type, by Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)Report

Oncology Companion Diagnostics Market by Type, by Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)

  • Published Date: ---
  • Base Year for Estimate:
  • Report ID: GVR5338
  • Format: Electronic (PDF)
  • Historical Data:
  • Number of Pages: 0

Increase in collaborations between key diagnostics manufacturers and pharmaceutical companies for the development of effective solutions to circumvent cancer management related challenges is driving the oncology companion diagnostics market. For instance, in January 2016, NanoString Technologies, Inc. signed an agreement with Astellas and Medivation to modify its PAM50-based Prosigna Breast Cancer Assay for use of this test as a potential CDx test with enzalutamide, a drug used to treat triple negative breast malignancy.

The use of companion diagnostics for oncology- clinical trials is rapidly increasing, as it offers several significant advantages, such as reduction in trial size and improvement in the success rate of different clinical trials. In addition, rising R&D investments in this market has resulted in a diversified pipeline of companion diagnostic tests designed for management of different tumor forms.

Non-small cell lung cancer, breast cancer, and colorectal cancer are recognized as the prominent cancer types with major revenue share in the market. This is due to a substantial number of ongoing clinical trials and high penetration of CDx for these types.

The technology progress in oncology companion diagnostics market is projected to gradually evolve from the “one biomarker, one disease” paradigm to “multiple biomarkers, one disease” or “one biomarker, multiple diseases”. Also, multi-biomarker assays are anticipated to become a standard of care as a result of rapid ongoing developments to boost the efficiency of these assays. This, in turn, is expected to contribute in the future adoption of these assays.

Furthermore, understanding the pivotal role of companion diagnostics in malignancies treatment, several pharmaceutical companies have begun incorporating biomarker panels in their therapy development protocols. For example, Ignyta Inc. has incorporated proprietary algorithm-based biomarker panels and NGS technology in its STARTRK-2 trial for identification and characterization of molecular or genetic variation in patients with malignancies. The trial is designed to investigate entrectinib’s effect against molecular variations including TrkA, TrkB, TrkC, ROS1, and ALK in patients.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified